|
| Press Releases |
|
 |
|
| Tuesday, September 24, 2024 |
|
|
China Medical System: New Drug Application for Vitiligo Indication of Ruxolitinib Phosphate Cream Accepted in China |
| China Medical System Holdings Limited (the "Company", together with its subsidiaries, the "Group" or "CMS") is pleased to announce that on September 24, 2024, the New Drug Application (NDA) for vitiligo indication of ruxolitinib phosphate cream (the "ruxolitinib cream" or the "Product") has been accepted by the National Medical Products Administration of China (NMPA). more info >> |
|
|
China Medical System: New Drug Application for Vitiligo Indication of Ruxolitinib Phosphate Cream Accepted in China |
| China Medical System Holdings Limited (the "Company", together with its subsidiaries, the "Group" or "CMS") is pleased to announce that on September 24, 2024, the New Drug Application (NDA) for vitiligo indication of ruxolitinib phosphate cream (the "ruxolitinib cream" or the "Product") has been accepted by the National Medical Products Administration of China (NMPA). more info >> |
|
|
康哲药业：磷酸芦可替尼乳膏（白癜风）中国上市许可申请已获受理 |
| 康哲药业控股有限公司（“本公司”，连同其附属公司统称为“本集团”或“康哲药业”）欣然宣布，磷酸芦可替尼乳膏（“芦可替尼乳膏”或“产品”）（白癜风适应症）新药上市许可申请（NDA）已于2024年9月24日获得中国国家药品监督管理局（NMPA）受理。 more info >> |
|
| Friday, August 16, 2024 |
|
|
康哲藥業（00867）發佈2024年中期業績：營業額和利潤環比均穩步提升 |
| 2024年8月15日，康哲藥業發佈2024年中期業績公告，整體營業額和期間利潤環比去年下半年穩步提升。2024年上半年實現營收36.11億元，同比下降21.7%，環比增長6.1%；若全按藥品銷售收入計算營收42.88億元，同比下降22.6%，環比增長8.9%；其中，非國採獨家產品及創新產品合計銷售收入為人民幣24.05億元，佔全按藥品銷售收入計算營業額的56.1%。實現淨利潤9.03億元，同比下降52.8%，環比大幅增長92.8%。 more info >> |
|
|
康哲药业（00867）发布2024年中期业绩：营业额和利润环比均稳步提升 |
| 康哲药业发布2024年中期业绩公告，整体营业额和期间利润环比去年下半年稳步提升。2024年上半年实现营收36.11亿元，同比下降21.7%，环比增长6.1%；若全按药品销售收入计算营收42.88亿元，同比下降22.6%，环比增长8.9%；其中，非国采独家产品及创新产品合计销售收入为人民币24.05亿元，占全按药品销售收入计算营业额的56.1%。实现净利润9.03亿元，同比下降52.8%，环比大幅增长92.8%。 more info >> |
|
|
China Medical System (00867) Released its 2024 Interim Results: Steady Increase in Revenue and Profit Compared with 2H 2023 |
| On August 15, 2024, China Medical System Holdings Limited ("CMS" or the "Company") released its 2024 interim results announcement, with a steady increase in overall revenue and profit for the period compared to the second half (2H) of 2023. In the first half (1H) of 2024, the Company recorded a turnover of RMB3,611.1 million, representing a decrease of 21.7% compared with 1H 2023, an increase of 6.1% compared with 2H 2023. more info >> |
|
|
China Medical System (00867) Released its 2024 Interim Results: Steady Increase in Revenue and Profit Compared with 2H 2023 |
| On August 15, 2024, China Medical System Holdings Limited ("CMS" or the "Company") released its 2024 interim results announcement, with a steady increase in overall revenue and profit for the period compared to the second half (2H) of 2023. In the first half (1H) of 2024, the Company recorded a turnover of RMB3,611.1 million, representing a decrease of 21.7% compared with 1H 2023, an increase of 6.1% compared with 2H 2023. more info >> |
|
| Tuesday, August 6, 2024 |
|
|
康哲药业：甲氨蝶呤注射液增加类风湿关节炎适应症中国NDA获批（更正版） |
| 康哲药业控股有限公司（“本公司”，连同其附属公司统称为“本集团”或“康哲药业”）欣然宣布，甲氨蝶呤注射液（“产品”）增加适应症的上市许可申请（NDA）已于2024年7月30日获得国家药品监督管理局（NMPA）批准。 more info >> |
|
|
康哲藥業：甲氨蝶呤注射液增加類風濕關節炎適應症中國NDA獲批 |
| 康哲藥業控股有限公司（“本公司”，連同其附屬公司統稱為“本集團”或“康哲藥業”）欣然宣佈，甲氨蝶呤注射液（“產品”）增加適應症的上市許可申請（NDA）已於2024年7月30日獲得國家藥品監督管理局（NMPA）批准。 more info >> |
|
| Monday, August 5, 2024 |
|
|
China Medical System: NDA for Additional Rheumatoid Arthritis Indication of Methotrexate Injection Approved in China |
| China Medical System Holdings Limited (the "Company", together with its subsidiaries, the "Group" or "CMS") is pleased to announce that on 30 July 2024, the New Drug Application (NDA) for an additional indication of Methotrexate Injection (the "Product") has been approved by the National Medical Products Administration of China (NMPA). more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
Hong Kong Films @ Busan 2024 opens tomorrow
Oct 4, 2024 22:00 HKT/SGT
|
|
|
Antidote Announces $100M for Community Building and User Rewards
Oct 4, 2024 20:00: JST
|
|
|
Antidote Announces $100M for Community Building and User Rewards
Oct 4, 2024 19:00 HKT/SGT
|
|
|
CNNが人々の生活をつなぐ医療の未来を探る特別番組「Tomorrow Transformed」を放送
Oct 4, 2024 19:00: JST
|
|
|
Indonesia's Path to Society 5.0: Driving Digital Innovation at the Digital Transformation Summit
Oct 4, 2024 16:34: JST
|
|
|
Indonesia's Path to Society 5.0: Driving Digital Innovation at the Digital Transformation Summit
Oct 4, 2024 15:34 HKT/SGT
|
|
|
三菱重工、防衛省向け3,000トン型潜水艦「ちょうげい」の命名式・進水式を神戸造船所で実施
Oct 4, 2024 15:00: JST
|
|
|
Honda、「N-BOX」が2024年度上半期 新車販売台数 第1位を獲得
Oct 4, 2024 15:00: JST
|
|
|
Pluk Phak Praw Rak Mae PCL (SET: OKJ) Eyes Expansion as the 'King of Organic Salad'
Oct 4, 2024 14:00 HKT/SGT
|
|
|
富士通、「人とAIのコラボレーションによる価値創造」をテーマに「CEATEC 2024」に出展
Oct 4, 2024 10:30: JST
|
|
|
Fujitsu highlights technologies to realize its vision of AI as a trusted assistant at CEATEC 2024
Oct 4, 2024 11:03 JST
|
|
|
Four major tech fairs open in October
Oct 3, 2024 22:09 HKT/SGT
|
|
|
AVIA Announces "Vietnam in View" Conference, Highlighting Growth and Opportunities in Vietnam's Media and Entertainment Industry
Oct 3, 2024 19:30 HKT/SGT
|
|
|
周大福人寿迈向40周年 推出“匠心-传承”储蓄寿险计划 2
Oct 3, 2024 18:42 HKT/SGT
|
|
|
周大福人壽邁向40周年 推出「匠心-傳承」儲蓄壽險計劃 2
Oct 3, 2024 17:03 HKT/SGT
|
|
|
|
|
More News >> |
|
|
|
|
|
